Cytochrome P450 3. Clinically Significant Drug Interactions
- 1 August 2000
- journal article
- research article
- Published by Wiley in The Australian Journal of Hospital Pharmacy
- Vol. 30 (4), 146-149
- https://doi.org/10.1002/jppr2000304146
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- EXTRAPOLATING IN VITRO DATA ON DRUG METABOLISM TO IN VIVO PHARMACOKINETICS: EVALUATION OF THE PHARMACOKINETIC INTERACTION BETWEEN AMITRIPTYLINE AND FLUOXETINEDrug Metabolism Reviews, 1999
- Drug Interactions with Tobacco SmokingClinical Pharmacokinetics, 1999
- IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3AAnnual Review of Pharmacology and Toxicology, 1998
- Inhibition and Induction of Cytochrome P450 and the Clinical ImplicationsClinical Pharmacokinetics, 1998
- Inhibition of Terfenadine Metabolism In Vitro by Azole Antifungal Agents and by Selective Serotonin Reuptake Inhibitor AntidepressantsJournal of Clinical Psychopharmacology, 1996
- A PRELIMINARY REPORT OF DILTIAZEM AND KETOCONAZOLETransplantation, 1994
- Pharmacokinetic Drug Interactions with RifampicinClinical Pharmacokinetics, 1992
- Interaction of citrus juices with felodipine and nifedipineThe Lancet, 1991
- Cimetidine inhibition of theophylline elimination: The influence of adult age and the time courseBiopharmaceutics & Drug Disposition, 1987